Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Ask the Analyst
Partnered Content
PDF Library
RSS Feeds
Subscribe
FAQs
Advertising
Report Store
UsernamePublicRestriction
Tags:

GSK R&D Initiative Sees Early Success: Phase II NCEs Up Three-Fold

  • News

Executive Summary

GlaxoSmithKline's R&D productivity program has experienced some early successes in the number of compounds coming out of the early-stage pipeline

You may also be interested in...



GSK’s New Oncology R&D Structure Reflects Personalized Medicine Emphasis

GlaxoSmithKline's creation of a separate "GSK Oncology" R&D unit is not only intended to capture efficiency and strengthen its position in the crowded field - the firm is also aiming to further its personalized medicine research

GSK’s New Oncology R&D Structure Reflects Personalized Medicine Emphasis

GlaxoSmithKline's creation of a separate "GSK Oncology" R&D unit is not only intended to capture efficiency and strengthen its position in the crowded field - the firm is also aiming to further its personalized medicine research

Pipeline Dreams: GSK’s Witty Outlines Plans To Lower Phase III Attrition

As Andrew Witty takes the helm at GlaxoSmithKline, he has set his sights on tackling one of the industry's biggest challenges: reducing attrition in the late-stage pipeline

Table

View full table

Related Content

Pink Sheet
Pink Sheet
Pink Sheet
Pink Sheet
Pink Sheet
Tags:
UsernamePublicRestriction

Register

LL1129367

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By